OPTiMiSE Optimization of Treatment and Management of Schizophrenia in Europe

Provider

Ministry of Education, Youth and Sports

Programme

—

Call for proposals

FP7-INCO-2013-1

Main participants

—

Contest type

RP - Co-financing of EC programme

Contract ID

MSMT-1840/2013-310

Project name in Czech

OPTiMiSE Optimization of Treatment and Management of Schizophrenia in Europe (Optimalizace léčby a postupu léčby schizofrenie v Evropě)

Annotation in Czech

The study is an international multicentric collaborative trial. This study will focus on two goals: optimising current treatments in schizophrenia and explore novel therapeutic options for schizophrenia. The study intends to both address basic, but so far unanswered, questions in the treatment of schizophrenia and develop new interventions. It is expected that the project will lead to evidence that is directly applicable to treatment guidelines, and will identify potential mechanisms for new drug development. Objectives: I To test applicability of amisulpride as the first step in a treatment algorithm. II To test guideline recommendation that non-responders to an antipsychotic drug benefit from a switch to an antipsychotic with a different receptor binding profile. III To provide the acceptability and outcome data on the application of clozapine in non-responding patients within the first 10 weeks of their treatment initiation. IV To test if an IT-enabled psychosocial intervention can improve treatment adherence and global functional outcome in symptomatically remitted first-episode schizophrenia patients. V To test whether glutamatergic markers predict response to first and second line treatments. VI To test if a combination of pharmacogenetic, proteomics- and metabolomic markers can provide clinical valuable predictive value. VII To define the nature and prevalence of ?organic? pathology in patients presenting with a first episode schizophreniform psychosis VIII To determine the extent to which MRI measures at first presentation predict the therapeutic response to subsequent antipsychotic treatment.

R&D category

AP - Applied research

CEP classification - main branch

FL - Psychiatry, sexology

CEP - secondary branch

EB - Genetics and molecular biology

CEP - another secondary branch

EA - Morphology and cytology

OECD FORD - equivalent branches <br>(according to the <a href="http://www.vyzkum.cz/storage/att/E6EF7938F0E854BAE520AC119FB22E8D/Prevodnik_oboru_Frascati.pdf">converter</a>)

10601 - Cell biology<br>10602 - Biology (theoretical, mathematical, thermal, cryobiology, biological rhythm), Evolutionary biology<br>10603 - Genetics and heredity (medical genetics to be 3)<br>10604 - Reproductive biology (medical aspects to be 3)<br>10605 - Developmental biology<br>10608 - Biochemistry and molecular biology<br>10609 - Biochemical research methods<br>30101 - Human genetics<br>30215 - Psychiatry<br>30301 - Social biomedical sciences (includes family planning, sexual health, psycho-oncology, political and social effects of biomedical research)

Provider evaluation

U - Uspěl podle zadání (s publikovanými či patentovanými výsledky atd.)

Project results evaluation

Following the condition that the candidate of financial contribution was evaluated and afterwards selected by international provider in accordance with the rules of the program the Ministry of Education, Youth ans Sports does not realize the evaluation of project results. The project is evaluated only after its approval by an international provider.

Realization period - beginning

Mar 1, 2012

Realization period - end

Feb 28, 2014

Project status

U - Finished project

Latest support payment

Mar 20, 2013

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data delivery code

CEP15-MSM-7E-U/01:1

Data delivery date

Jul 2, 2015

Total approved costs

301 thou. CZK

Public financial support

301 thou. CZK

Other public sources

0 thou. CZK

Non public and foreign sources

0 thou. CZK